AstronauTx, a pioneering UK-based company, focuses on rectifying disrupted brain physiology to combat neurodegenerative diseases. These diseases, including Alzheimer's and Parkinson's, are characterised by the accumulation of pathological proteins such as β-amyloid, tau, and α-synuclein.

AstronauTx targets mechanisms aimed at enhancing the clearance of toxic substances from the brain, facilitating memory consolidation, boosting metabolism for efficient network function, and promoting long-term neuronal health. By improving protective clearance mechanisms and memory consolidation, the company aims to prevent further toxin deposition and the spread of toxic misfolded proteins driving neurodegenerative diseases.

Additionally, AstronauTx seeks to enhance neural support through the provision of energy and growth factors, maintaining metabolic, synaptic, and network health to improve neurophysiological function. The company's approach is multifactorial, with a focus on both symptom relief and disease modification.